**Name of journal:** *World Journal of Clinical Urology*

**ESPS Manuscript NO: 3225**

**Columns: BRIEF ARTICLE**

**Potential of metastin and metastin receptor as biomarkers for urological cancers**

**Shoji S *et al*.**Metastin in urological cancers

Sunao Shoji, Haruhiro Sato, Tetsuro Tomonaga, Hakushi Kim, Shuichi Soeda, Mayura Nakano, Toyoaki Uchida, Toshiro Terachi, Koichi Takeya

**Sunao Shoji, Tetsuro Tomonaga, Hakushi Kim, Toyoaki Uchida,** Department of Urology, Tokai University Hachioji Hospital, Hachioji, Tokyo 192-0032, Japan

**Haruhiro Sato,** Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan

**Shuichi Soeda,** Department of Urology, Tokai University Oiso Hospital, Naka-gun, Kanagawa 259-0198, Japan

**Mayura Nakano,** Department of Urology, Numazu City Hospital, Numazu, Shizuoka 410-0302, Japan

**Toshiro Terachi,** Department of Urology, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan

**Koichi Takeya,** Department of Natural Products and Medical Chemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0355, Japan

**Author contributions**: Shoji S designed research and performed research; Shoji S, Sato H, Tomonaga T, Kim H, Soeda S, Nakano M, Uchida T, Terachi T, Takeya K analyzed data; Shoji S wrote the paper; an author may list more than one contribution, and more than one author may have contributed to the same aspect.

**Correspondence to: Sunao Shoji, MD, PhD,** Department of Urology, Tokai University Hachioji Hospital, 1838 Ishikawa-machi, Hachioji, Tokyo 192-0032, Japan.

sunashoj@mail.goo.ne.jp

**Telephone:** +81-42-6391111 **Fax:** +81-42-6391111

**Received:** April 15, 2013  **Revised:** May 31, 2013

**Accepted:** June 8, 2013

 **Published online:**

**Abstract**

**AIM:**To investigate the current state of the research of metastin and metastin receptor in the urological cancer field.

**METHODS:** For analyzing the value of metastin and metastin receptor as molecular biomarkers for the patients with urological cancer, MEDLINE database searches were performed using these terms: metastin, KISS1, kisspeptin, renal (cell) carcinoma (RCC), kidney cancer or urothelial cancer or bladder cancer or prostate cancer or testicular cancer (tumor). Since the articles were evaluated by the validity of the articles based on plausibility, credibility, and evidence levels, the articles were graded according to their level of evidence, using the grading system defined by the Oxford Centre for Evidence-based Medicine.

**RESULTS:** A total of six clinical studies published by individual institutions between 2003 and 2013 were included in this review. The article numbers for each of the evidence levels 2a and 2b were three (50%) and three (50%), respectively. Immunohistochemistry and reverse transcriptase-polymerase chain reaction using tumor tissues were performed to analyze in five articles (83%) and in one article (17%). The value of metastin and/or metastin receptor as molecular biomarkers in clear cell RCC, upper tract urothelial carcinoma, and bladder cancer was evaluated by multivariate analysis. Low expression of metastin receptor in clear cell RCC and low expression of metastin in upper tract urothelial carcinoma were significant risk factors for metastasis, and low metastin expression was an independent prognostic factor in bladder cancer.

**CONCLUSION:** Metastin and metastin receptor have potential as suitable molecular biomarkers for urological cancers. However, future studies of metastin and metastin receptor should undergo external validation to ensure consistency across different

patient series, since individual institutional studies lack generalization.

© 2013 Baishideng. All rights reserved.

**Key words**: *KISS-1*; Metastin; Metastin receptor; Metastasis; Renal cell carcinoma; Upper tract urothelial carcinoma; Bladder cancer

**Core tip:** Metastin and metastin receptor have attracted interest in the field of cancer because of their novelty and potential to inhibit cancer metastasis. Furthermore, they have potential as suitable molecular biomarkers for urological cancers. However, the results of all of the studies analyzed in this review were retrospectively obtained. Therefore, future studies of metastin and metastin receptor should undergo external validation to ensure consistency across different patient series, since individual institutional studies lack generalization.

Shoji S, Sato H, Tomonaga T, Kim H, Soeda S, Nakano M, Uchida T, Terachi T, Takeya K. Potential of metastin and metastin receptor as biomarkers for urological cancers. *World J Clin Urol* 2013*;*

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** http://dx.doi.org/10.5410/wjcu.v0.i0.0000

**INTRODUCTION**

Cancer metastasis is a leading cause of death in cancer patients. Metastasis is a complex, multistage process in which malignant tumor cells spread from the primary tumor to secondary organs. Tumor cells acquire an invasive phenotype to invade the stromal tissue and disrupt the vascular endothelium. Once in the blood, the disseminated tumor cells (DTCs) must survive in the circulating environment and escape physical damage and attack by the immune system. After the tumor cells arrest or adhere to vessel walls, they invade through the capillary wall (extravasation)[1,2]. Finally, DTCs must adapt to the new microenvironment of the secondary site and start to form micrometastasis or reprogram to a quiescent state, which can last for years[1,2]. The metastasis suppressor genes are defined by their ability to prevent the development of metastasis by inducing apoptosis or dormancy once the cells have lodged at the secondary site. The proteins encoded by these genes participate in a diverse range of signaling pathways, and in some cases they inhibit not just one but multiple steps in the metastatic cascade[2]. The *KISS-1* cancer metastasis suppressor gene is located on human chromosome 1q32[3], and encodes a carboxy-terminal amidated peptide with 54 amino acid residues called metastin (kisspeptin), which was identified as the ligand of a G-protein-coupled receptor, the metastin receptor[4]. Metastin and metastin receptor inhibit tumor invasion or migration through focal adhesion kinase, paxillin, MAP kinase or RhoA, and have been implicated in melanoma, thyroid cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, pancreatic carcinoma, breast cancer, ovarian cancer, RCC, upper tract urothelial carcinoma, bladder cancer, and prostate cancer[5-7]. Furthermore, metastin and metastin receptor were shown to be expressed in the hypothalamus, brain stem, spinal cord, pituitary, ovary, prostate and placenta in normal human tissue, and they play a pivotal role in the control of the hypothalamic pituitary–gonadal axis *via* regulation of gonadotropin-releasing hormone secretion[8].

The objective of this review article was to investigate the value of metastin and metastin receptor in urological cancers.

**MATERIALS AND METHODS**

To analyze the clinical study of metastin and/or metastin receptor, MEDLINE database searches were performed using the following terms: metastin, *KISS-1*, kisspeptin, renal (cell) carcinoma or kidney cancer, urothelial carcinoma or bladder cancer or prostate cancer or testicular cancer. Since the articles were evaluated by the validity of the articles based on plausibility, credibility, and evidence levels[9], the articles were graded according to their level of evidence using the grading system defined by the Oxford Centre for Evidence-based Medicine[10].

**RESULTS**

***Current state of the literature for metastin and metastin receptor in urological cancer***

A total of six articles published between 2003 and 2013 were included in this review. The majority of the data were predominantly obtained *via* nonrandomized, retrospective, but often controlled studies. Immunohistochemistry (IHC) and reverse transcriptase-polymerase chain reaction analyses of tumor tissues were performed in five articles (83%)[6,11-14] and in one article (17%)[15]. Thus, the article numbers for each of the evidence levels[10] 2a and 2b were three (50%) and three (50%), respectively (Table 1).

***Summary of the clinical studies of metastin and metastin receptor in urological cancer***

**Renal cell carcinoma:** Metastin receptor was reported as being more highly expressed in RCCs compared to normal tissue[11,16]. Chen *et al*[11] reported that lack of metastin receptor was correlated with rapid progression of clear cell RCC. In an IHC study of 131 patients with clear cell RCC, the absence of metastin receptor was significantly associated with a poor overall or tumor-specific survival in Kaplan–Meier survival analysis (*P* < 0.0001)[11]. Furthermore, 121 patients with clear cell RCC exhibited positive staining of low to high metastin receptor expression, and the remaining 10 patients with negative immunostaining died because of tumor progression. However, the expression of metastin had no correlation with tumor-specific survival (*P* = 0.778)[11]. Shoji *et al*[12] reported that lack of metastin receptor is a predictor of metastasis after radical nephrectomy for pT1 clear cell RCC. IHC analysis of samples from 54 patients with clear cell RCC revealed that the sensitivity, specificity, positive predictive value, and negative predictive value with negative immunostaining of metastin receptor were 85.7%, 97.6%, 46.2%, and 97.6%, respectively[12]. Metastasis-free survival rates were significantly higher in patients with positive staining (97.6%) than in patients with negative staining (53.8%) (*P* < 0.001)[12]. In univariate analysis for metastasis-free survival, negative immunostaining of metastin receptor was a significant risk factor for metastasis (*P* = 0.001)[12]. Furthermore, negative immunostaining of metastin receptor was an independent predictor for metastasis in multivariate analysis (*P* = 0.002) [12].

**Upper urinary tract urothelial carcinoma:** Takeda *et al*[6] reported that 44 patients (29.1%) had distant metastasis during follow-up; 39.1% (27 of 69 patients) with low metastin expression compared with 20.7% (17 of 82 patients) with high metastin expression in an IHC study of 151 patients with upper urinary urothelial carcinoma. Univariate analysis revealed that low metastin expression, pT2 or greater, and positive lymphovascular invasion were significant risk factors for metastasis[6]. In multivariate analysis, low metastin expression (*P* = 0.028), pT2 or greater (*P* = 0.013), and positive lymphovascular invasion (*P* < 0.001) were independent predictors for metastasis[6]. The 5-year metastasis-free survival rates were 60.9% for the patients with low expression of metastin and 81.0% for patients with high expression of metastin (*P* = 0.012)[6].

**Bladder cancer:** Metastin was reported to be highly expressed in bladder cancers[13,14].Sanchez-Carbayo *et al*[13] reported that metastin expression was significantly associated with stage (*P* = 0.031) and not with tumor grade. In an IHC study of 69 patients with bladder cancer, mean survival time and median survival time of patients with expression lower than 20% was 14.7 and 9.0 mo, respectively[13]. Furthermore, mean survival time and median survival time of patients with expression higher than 20% was 47.3 and 37.0 mo, respectively[13]. Nicolle *et al*[14] reported that metastin receptor was expressed at high levels in bladder cancers compared with normal bladder tissue, and the difference between low- and high-grade groups was significant (*P* = 0.03). However, there was no association between the expression of metastin and grade[14]. The researchers suggested that the expression of metastin receptor is highly deregulated in invasive and high-grade tumors more often than in superficial and low-grade tumors[14]. Cebrian *et al*[15] reported that upregulated metastin expression was found in low-grade and early lesions, compared with high-grade (*P* = 0.010) and invasive bladder tumors (*P* = 0.001). They reported that tumors with metastin methylation had lower transcript expression than unmethylated tumors (*P* = 0.037), and low transcript levels of metastin were significantly associated with increasing stage (*P* < 0.0005) and grade (*P* = 0.024)[15]. In a series of 205 patients with bladder cancer, high expression of metastin indicated favorable outcomes. Furthermore, multivariate analysis indicated that metastin expression and tumor stage were independent prognostic factors (*P* = 0.001), with hazard ratios of death of 2.62 (95%CI 1.49–4.58; *P* = 0.001) and 0.42 (95%CI 0.20–0.85; *P* = 0.017), respectively[15].

**DISCUSSION**

In the current review, the value of metastin and/or metastin receptor as molecular biomarkers in clear cell RCC[12], upper tract urothelial carcinoma[6], and bladder cancer[15] were evaluated in a multivariate analysis of clinical studies. Low expression of metastin receptor in clear cell RCC and low expression of metastin in upper tract urothelial carcinoma were found to be significant risk factors for metastasis[6,12], and low expression of metastin was an independent prognostic factor in bladder cancer[15]. However, the results showed that the data in all of the studies were obtained retrospectively. An increasing number of molecular biomarkers have been investigated by numerous teams, with inherent differences regarding population size, demographics, techniques used, and interpretation of results. However, many negative findings have not been published as a result of a lack of enthusiasm by researchers to declare negative findings and because of the reluctance of scientific journals to publish negative reports, thus lending bias to the overall field. Therefore, all studies of molecular biomarker including metastin and metastin receptor should undergo external validation to ensure consistency across different patient series, since individual institutional studies lack generalization[17].

Metastin receptor was found by Ohtaki *et al*[4] as a rat orphan receptor (rOT7T175) that was nearly identical to GPR54 during a search for novel G-protein-coupled receptors using a degenerate polymerase chain reaction strategy. To identify the endogenous ligand of a human orphan receptor, these authors established a stable CHO cell line expressing the human counterpart metastin receptor (CHO/h175). Although hOT7T175 has 39.2% amino-acid identity to human galanin receptor GALR2, the cells did not show any response to a panel of known peptides, including galanin and galanin-like peptides. However, human placental extract induced a robust increase in the intracellular calcium ion concentration ([Ca2+]i) in CHO/h175 cells. The amino-terminal sequence obtained for the isolated peptide was identical to the partial amino-acid sequence (Gly 68 to Ala 88) of the *KISS-1* gene product. This sequence was isolated from human placenta as the endogenous ligand of an orphan G-protein-coupled receptor and was termed “metastin”[4]. For the function of metastin as a metastasis suppressor protein, excessive formation of focal adhesion and stress fibers by phosphorylation of focal adhesion kinase and paxillin in cells expressing metastin receptor might be one of the mechanisms through which tumor metastasis is inhibited by metastin[4,18-20]. Takino *et al*[21] reported that metastin forms a complex with pro- matrix metalloprotease (MMP) and active MMP-2, while MMP-9, matrix type (MT) 1-MMP, MT3-MMP and MT5-MMP cleave the Gly118-Leu119 peptide bond of both full-length metastin and metastin decapeptide. MMP plays an important role in development and morphogenesis by participating in extracellular matrix re-modeling[22]. Cancer cells also use MMP for invasion and metastasis. Invading cells are forced to proliferate within an embedded dense three-dimensional matrix composed largely of type I collagen or cross-linked fibrin[23-26]. Moreover, digestion of the metastin decapeptide by MMP abolished its ligand activity. Takino *et al*[21] proposed that: (1) metastin is used as an antimetastatic agent in combination with MMP inhibitor; or (2) MMP-resistant forms of metastin are developed that may also be efficacious.

The mechanisms of metastin and metastin receptor as metastasis suppressor proteins in urological cancers were hypothesized[6,13,16]. In RCC, metastin induced excessive formation of focal adhesions in RCC cell lines, which are located at the ends of stress fibers in RCC cell lines[16]. The results of these experiences suggested that metastin regulates focal adhesion and metastasis through the Rho-GTPase route by activating one or several of its members[16]. In urothelial carcinoma, metastin significantly reduced the invasiveness of a bladder cancer cell line and inhibited the DNA-binding activity of nuclear factor kappa B by blocking its nuclear translocation, leading to a reduction in the expression and activity of MMP-9[6]. In another study, metastin function was considered as an upstream regulator of E-cadherin[13]. Furthermore, metastin was aberrantly silenced by CpG island hypermethylation in bladder cancer cell lines[15]. In bladder cancer, the increased methylation rate together with the loss of transcript expression of *KISS-1* was also found to be associated with increasing tumor stage and poor clinical outcome[15].

Wang *et al*[7] reported the potential of metastin as a molecular biomarker for predicting prognosis in patients with prostate cancer. *In* *vitro*, metastin inhibited the invasion of a prostate cancer cell line, PC-3M. Furthermore, IHC staining showed weak or lack of metastin expression in prostate cancer tissue[7]. Although no significant difference in metastin expression was observed between primary and metastatic tissues (*P* = 0.3), loss of metastin expression was positively correlated with clinical stages II/III, IV and metastatic tumors (*P* < 0.01), and metastin expression was significantly lower in metastatic tissues than in earlier stage primary prostate cancer (*P* < 0.01), indicating that loss of metastin expression correlated with prostate cancer progression[7]. Moreover, the expression of metastin receptor was weak and only mildly positive in normal prostate tissues, and decreased expression was observed in primary and metastatic tissues[7].

In conclusion, metastin and metastin receptor have attracted interest in the field of cancer because of their novelty and potential to inhibit cancer metastasis. Furthermore, they have potential as suitable molecular biomarkers for urological cancers. However, the results of all of the studies analyzed in this review were retrospectively obtained. Therefore, future studies of metastin and metastin receptor should undergo external validation to ensure consistency across different patient series, since individual institutional studies lack generalization.

**COMMENTS**

***Background***

Cancer metastasis is a leading cause of death in cancer patients. Metastasis is a complex, multistage process in which malignant tumor cells spread from the primary tumor to secondary organs. The KISS-1 cancer metastasis suppressor gene is located on human chromosome 1q32, and encodes a carboxy-terminal amidated peptide with 54 amino acid residues called metastin (kisspeptin), which was identified as the ligand of a G-protein-coupled receptor, the metastin receptor. Metastin and metastin receptor inhibit tumor invasion or migration through focal adhesion kinase, paxillin, mitogen-activated protein kinase or RhoA, and have been implicated in melanoma, thyroid cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, pancreatic carcinoma, breast cancer, ovarian cancer, renal (cell) carcinoma (RCC), upper tract urothelial carcinoma, bladder cancer, and prostate cancer.

***Research frontiers / Innovations and breakthroughs***

In the current review, the value of metastin and/or metastin receptor as molecular biomarkers in clear cell RCC, upper tract urothelial carcinoma, and bladder cancer were evaluated in a multivariate analysis of clinical studies. Low expression of metastin receptor in clear cell RCC and low expression of metastin in upper tract urothelial carcinoma were found to be significant risk factors for metastasis, and low expression of metastin was an independent prognostic factor in bladder cancer.

***Applications***

Metastin and metastin receptor have attracted interest in the field of cancer because of their novelty and potential to inhibit cancer metastasis. Furthermore, they have potential as suitable molecular biomarkers for urological cancers.

***Peer review***

This paper is meaningful because a description of metastin and metastin receptor was clearfied as suitable molecular biomarkers for urological cancers.

**REFERENCES**

1 **Páez D**, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ. Cancer dormancy: a model of early dissemination and late cancer recurrence. *Clin Cancer Res* 2012; **18**: 645-653 [PMID: 22156560 DOI: 10.1158/1078-0432.CCR-11-2186]

2 **Horak CE**, Lee JH, Marshall JC, Shreeve SM, Steeg PS. The role of metastasis suppressor genes in metastatic dormancy. *APMIS* 2008; **116**: 586-601 [PMID: 18834404 DOI: 10.1111/j.1600-0463.2008.01213.x]

3 **West A**, Vojta PJ, Welch DR, Weissman BE. Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1). *Genomics* 1998; **54**: 145-148 [PMID: 9806840 DOI: 10.1006/geno.1998.5566]

4 **Ohtaki T**, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, Ishibashi Y, Watanabe T, Asada M, Yamada T, Suenaga M, Kitada C, Usuki S, Kurokawa T, Onda H, Nishimura O, Fujino M. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. *Nature* 2001; **411**: 613-617 [PMID: 11385580 DOI: 10.1038/35079135]

5 **Shoji S**, Tang XY, Sato H, Usui Y, Uchida T, Terachi T. Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review). *Oncol Lett* 2010; **1**: 783-788 [PMID: 22966379 DOI: 10.3892/ol\_00000136]

6 **Takeda T**, Kikuchi E, Mikami S, Suzuki E, Matsumoto K, Miyajima A, Okada Y, Oya M. Prognostic role of KiSS-1 and possibility of therapeutic modality of metastin, the final peptide of the KiSS-1 gene, in urothelial carcinoma. *Mol Cancer Ther* 2012; **11**: 853-863 [PMID: 22367780 DOI: 10.1158/1535-7163.MCT-11-0521]

7 **Wang H**, Jones J, Turner T, He QP, Hardy S, Grizzle WE, Welch DR, Yates C. Clinical and biological significance of KISS1 expression in prostate cancer. *Am J Pathol* 2012; **180**: 1170-1178 [PMID: 22226740 DOI: 10.1016/j.ajpath.2011.11.020]

8 **Roseweir AK**, Millar RP. The role of kisspeptin in the control of gonadotrophin secretion. *Hum Reprod Update* 2009; **15**: 203-212 [PMID: 19109311 DOI: 10.1093/humupd/dmn058]

9 **Hammersley M**. Reading ethnographic research : a critical guide. 2nd ed. London; New York: Longman, 1998

10 Centre for Evidenced-Based Medicine. In: Secondary Centre for Evidenced-Based Medicine; 2009Available from: URL: http: //www.cebm.net/?o=1025

11 **Chen Y**, Yusenko MV, Kovacs G. Lack of KISS1R expression is associated with rapid progression of conventional renal cell carcinomas. *J Pathol* 2011; **223**: 46-53 [PMID: 20922711 DOI: 10.1002/path.2764]

12 **Shoji S**, Nakano M, Tomonaga T, Kim H, Hanai K, Usui Y, Nagata Y, Miyazawa M, Sato H, Tang XY, Osamura YR, Uchida T, Terachi T, Takeya K. Value of metastin receptor immunohistochemistry in predicting metastasis after radical nephrectomy for pT1 clear cell renal cell carcinoma. *Clin Exp Metastasis* 2013; In press

13 **Sanchez-Carbayo M**, Capodieci P, Cordon-Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. *Am J Pathol* 2003; **162**: 609-617 [PMID: 12547718 DOI: 10.1016/S0002-9440(10)63854-0]

14 **Nicolle G**, Comperat E, Nicolaïew N, Cancel-Tassin G, Cussenot O. Metastin (KISS-1) and metastin-coupled receptor (GPR54) expression in transitional cell carcinoma of the bladder. *Ann Oncol* 2007; **18**: 605-607 [PMID: 17164231 DOI: 10.1093/annonc/mdl421]

15 **Cebrian V**, Fierro M, Orenes-Piñero E, Grau L, Moya P, Ecke T, Alvarez M, Gil M, Algaba F, Bellmunt J, Cordon-Cardo C, Catto J, López-Beltrán A, Sánchez-Carbayo M. KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. *Am J Pathol* 2011; **179**: 540-546 [PMID: 21683672 DOI: 10.1016/j.ajpath.2011.05.009]

16 **Shoji S**, Tang XY, Umemura S, Itoh J, Takekoshi S, Shima M, Usui Y, Nagata Y, Uchida T, Osamura RY, Terachi T. Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor. *Eur Urol* 2009; **55**: 441-449 [PMID: 18395325 DOI: 10.1016/j.eururo.2008.02.048]

17 **Bleeker SE**, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, Grobbee DE, Moons KG. External validation is necessary in prediction research: a clinical example. *J Clin Epidemiol* 2003; **56**: 826-832 [PMID: 14505766]

18 **Kotani M**, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, Brézillon S, Tyldesley R, Suarez-Huerta N, Vandeput F, Blanpain C, Schiffmann SN, Vassart G, Parmentier M. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. *J Biol Chem* 2001; **276**: 34631-34636 [PMID: 11457843 DOI: 10.1074/jbc.M104847200]

19 **Hori A**, Honda S, Asada M, Ohtaki T, Oda K, Watanabe T, Shintani Y, Yamada T, Suenaga M, Kitada C, Onda H, Kurokawa T, Nishimura O, Fujino M. Metastin suppresses the motility and growth of CHO cells transfected with its receptor. *Biochem Biophys Res Commun* 2001; **286**: 958-963 [PMID: 11527393 DOI: 10.1006/bbrc.2001.5470]

20 **Yan C**, Wang H, Boyd DD. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha -induced block of p65/p50 nuclear translocation. *J Biol Chem* 2001; **276**: 1164-1172 [PMID: 11060311 DOI: 10.1074/jbc.M008681200]

21 **Takino T**, Koshikawa N, Miyamori H, Tanaka M, Sasaki T, Okada Y, Seiki M, Sato H. Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. *Oncogene* 2003; **22**: 4617-4626 [PMID: 12879005 DOI: 10.1038/sj.onc.1206542]

22 **Liotta LA**, Thorgeirsson UP, Garbisa S. Role of collagenases in tumor cell invasion. *Cancer Metastasis Rev* 1982; **1**: 277-288 [PMID: 6309368]

23 **Fisher KE**, Sacharidou A, Stratman AN, Mayo AM, Fisher SB, Mahan RD, Davis MJ, Davis GE. MT1-MMP- and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices. *J Cell Sci* 2009; **122**: 4558-4569 [PMID: 19934222 DOI: 10.1242/jcs.050724]

24 **Makareeva E**, Han S, Vera JC, Sackett DL, Holmbeck K, Phillips CL, Visse R, Nagase H, Leikin S. Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. *Cancer Res* 2010; **70**: 4366-4374 [PMID: 20460529 DOI: 10.1158/0008-5472]

25 **Maquoi E**, Assent D, Detilleux J, Pequeux C, Foidart JM, Noël A. MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis. *Oncogene* 2012; **31**: 480-493 [PMID: 21706048 DOI: 10.1038/onc.2011.249]

26 **Sarkar SK**, Marmer B, Goldberg G, Neuman KC. Single-molecule tracking of collagenase on native type I collagen fibrils reveals degradation mechanism. *Curr Biol* 2012; **22**: 1047-1056 [PMID: 22578418 DOI: 10.1016/j.cub.2012.04.012]

**P-Reviewers** Ali-El-Dein B, Shoji S **S-Editor** Gou SX

**L-Editor E-Editor**

**Table 1 Summary of metastin and/or metastin receptor literature in the urological cancer field**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Author (yr)** | **Patients (*n*)** | **The methods of the analyses (sample type)** | **Evidence level[14]** |
| Renal cell carcinoma | Chen *et al*[11] | 131 | IHC(tumor tissue) | 2a |
| Shoji *et al*[12]  | 54 | IHC(tumor tissue) | 2a |
| Urothelial carcinoma | Takeda *et al*[6] | 151 | IHC(tumor tissue) | 2b |
| Bladder cancer | Sanchez-Carbayo *et al*[13] | 69 | IHC(tumor tissue) | 2a |
| Nicolle *et al*[14] | 64 | IHC(tumor tissue) | 2b |
| Cebrian *et al*[15] | 205 | RT-PCR(tumor tissue) | 2b |

RT-PCR: Reverse transcriptase-polymerase chain reaction; IHC: Immunohistochemical analysis. Level 2a: Systematic review (with homogeneity) of either retrospective cohort studies or untreated control groups in randomized controlled trials; Level 2b: Retrospective cohort study or follow-up of untreated control patients in a randomized controlled trial; or derivation of a clinical decision rule or validated on split-sample only.